UPDATE: Leerink Says Tekmira Is 'Uniquely Positioned'
The company has significant opportunity beyond Ebola with its RNAi product and pipeline, according to the research report. These factors make Tekmira “uniquely positioned.”
TKM-HBV, Tekmira’s hepatitis B drug has the potential to be a major growth catalyst says analyst Michael Schmidt. An investigational new drug application is expected to be filed in the second half of 2015.
Related Link: Deutsche Bank Raises Achillion Price Target 138%
Tekmira shares are up 106 percent over the past month; the company is one of few names mentioned in the recent Ebola outbreak. Shares fell 50 percent from peak to trough last week, but today’s rally is fueling a recovery.
The issue was last trading hands at $19.30, a 6.75 percent gain.
Latest Ratings for TKMR
|Nov 2014||Stifel Nicolaus||Maintains||Buy|
|Oct 2014||Leerink Swann||Downgrades||Outperform||Market Perform|
|Aug 2014||Leerink Partners||Initiates Coverage on||Outperform|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.